What is the 13F Pro Quality Score for FULC?

13F Pro ranks Fulcrum Therapeutics, Inc. (FULC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View FULC's current score at https://13fpro.ai/company/FULC (free sign-up required for the full ranking).

Which hedge funds own the most FULC stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of FULC include BlackRock,, EcoR1 Capital,, TANG CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/FULC as soon as new 13F filings post.

Where does 13F Pro source FULC data?

All Fulcrum Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Fulcrum Therapeutics, Inc. files with the SEC under CIK 1680581. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is FULC in?

Fulcrum Therapeutics, Inc. (FULC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is FULC research updated on 13F Pro?

FULC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Fulcrum Therapeutics, Inc.(FULC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1680581 FULC stock profile & AI dashboard →

13F Pro Quality Score

32.9/100

Rank #2,179 of 2,719 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

99.7/100

Profitability

7.8/100

Balance Sheet

8.2/100

Earnings Quality

18.0/100

Free Cash Flow

6.8/100

Institutional Flow

83.1/100

Revenue Scale

14.0/100

Dilution Risk

8.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why FULC Scores 33/100

exact factor attribution · 2026-02-20

FULC's composite is driven by revenue growth and institutional flow, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.9 pts

100th pct

Institutional flow

+1.6 pts

83th pct

Earnings growth

-1.0 pts

30th pct

Shareholder dilution

-2.1 pts

9th pct

Earnings quality

-3.2 pts

18th pct

Capital efficiency

-4.2 pts

8th pct

Scale

-5.4 pts

14th pct

Profitability

-6.3 pts

8th pct

Free cash flow

-6.5 pts

7th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in FULC

Events flagged as statistical outliers against FULC's own multi-year baseline — not fixed dollar thresholds.

Record insider buy2026-07-16
Largest insider buy on record for FULC: TANG KEVIN purchased $415,349
View source filing →

FULC Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Fulcrum Therapeutics, Inc. (FULC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FULC at 32.9/100 on a 32-signal composite quality model, placing it at rank #2,179 of 2,719 stocks — the bottom half of the AI-ranked universe. FULC scores in the top quartile across revenue growth (99.7), institutional flow (83.1). Areas of concern include free cash flow (6.8) and profitability (7.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Fulcrum Therapeutics, Inc. reports net income of $-26.2M, free cash flow of $-16.1M. Top institutional holders of FULC by reported 13-F value include BlackRock, EcoR1 Capital, TANG CAPITAL MANAGEMENT, based on the most recent SEC filings. FULC trades on the Nasdaq exchange and files with the SEC under CIK 1680581. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FULC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Fulcrum Therapeutics, Inc. directly from SEC EDGAR. Fulcrum Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 3 and 40 since 2022, currently 32.9 — an improving long-term trajectory across 17 quarterly and live scoring snapshots.

Net Income

Q2 2026

$-26.2M

Free Cash Flow

Q2 2026

$-16.1M

ROIC

Q2 2026

-37.7%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-100.0% YoY

$0.00FY 2025

FY22 $6.3MFY23 $2.8MFY24 $80.0MFY25 $0.00

Net Income

-670.0% YoY

$-74.9MFY 2025

FY22 $-109.9MFY23 $-97.3MFY24 $-9.7MFY25 $-74.9M

Operating Income

-287.1% YoY

$-84.8MFY 2025

FY22 $-112.6MFY23 $-110.7MFY24 $-21.9MFY25 $-84.8M

EPS (Diluted)

-637.5% YoY

$-1.18FY 2025

FY22 $-2.44FY23 $-1.59FY24 $-0.16FY25 $-1.18

Total Assets

+40.5% YoY

$366.3MFY 2025

FY22 $226.7MFY23 $257.7MFY24 $260.7MFY25 $366.3M

Op. Cash Flow

-2608.1% YoY

$-60.1MFY 2025

FY22 $-97.0MFY23 $-91.0MFY24 $-2.2MFY25 $-60.1M

Free Cash Flow

-2319.0% YoY

$-60.4MFY 2025

FY22 $-99.0MFY23 $-91.5MFY24 $-2.5MFY25 $-60.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$0.00 -100.0%	$80.0M +2752.0%	$2.8M -55.8%	$6.3M -66.9%	$19.2M +117.2%	$8.8M
Net Income	$-74.9M -670.0%	$-9.7M +90.0%	$-97.3M +11.4%	$-109.9M -35.9%	$-80.8M -14.2%	$-70.8M
Operating Income	$-84.8M -287.1%	$-21.9M +80.2%	$-110.7M +1.7%	$-112.6M -38.9%	$-81.1M -13.2%	$-71.6M
EPS (Diluted)	$-1.18 -637.5%	$-0.16 +89.9%	$-1.59 +34.8%	$-2.44 -6.6%	$-2.29 +17.9%	$-2.79
Total Assets	$366.3M +40.5%	$260.7M +1.2%	$257.7M +13.7%	$226.7M -3.5%	$235.0M +81.4%	$129.6M
Operating Cash Flow	$-60.1M -2608.1%	$-2.2M +97.6%	$-91.0M +6.3%	$-97.0M -23.7%	$-78.5M -46.3%	$-53.7M
Free Cash Flow	$-60.4M -2319.0%	$-2.5M +97.3%	$-91.5M +7.6%	$-99.0M -23.5%	$-80.2M -45.8%	$-55.0M

Get alerted when FULC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Fulcrum Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of FULC

BlackRock, Inc.
$32.3M8,824,259 sh
EcoR1 Capital, LLC
$24.0M6,549,866 sh
TANG CAPITAL MANAGEMENT LLC
$23.9M6,521,412 sh
Nantahala Capital Management, LLC
$20.0M5,475,040 sh
SUVRETTA CAPITAL MANAGEMENT, LLC
$13.5M3,680,921 sh
D. E. Shaw & Co., Inc.
$11.1M3,044,385 sh
CITADEL ADVISORS LLC
$9.9M2,704,505 sh
VANGUARD CAPITAL MANAGEMENT LLC
$9.9M2,697,216 sh
JANE STREET GROUP, LLC
$8.1M2,217,498 sh
STATE STREET CORP
$7.5M2,037,025 sh

Fund	Value	Shares
BlackRock, Inc.	$32.3M	8,824,259
EcoR1 Capital, LLC	$24.0M	6,549,866
TANG CAPITAL MANAGEMENT LLC	$23.9M	6,521,412
Nantahala Capital Management, LLC	$20.0M	5,475,040
SUVRETTA CAPITAL MANAGEMENT, LLC	$13.5M	3,680,921
D. E. Shaw & Co., Inc.	$11.1M	3,044,385
CITADEL ADVISORS LLC	$9.9M	2,704,505
VANGUARD CAPITAL MANAGEMENT LLC	$9.9M	2,697,216
JANE STREET GROUP, LLC	$8.1M	2,217,498
STATE STREET CORP	$7.5M	2,037,025

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put FULC on your watchlist

Track score changes the day Fulcrum Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is FULC a good stock to buy?

13F Pro's AI-powered analysis of Fulcrum Therapeutics, Inc. (FULC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FULC are available on the FULC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. FULC is classified as a small company.

Which hedge funds own FULC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FULC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Fulcrum Therapeutics, Inc.'s investment landscape.